神经退行:来自Eremurus persicus的代谢物可以帮助吗?
Valeria Cavalloro1,2, Nicoletta Marchesi3, Pasquale Linciano3
1Department of Earth and Environmental Sciences, University of Pavia, Pavia, Italy.
Frontiers in pharmacology
|February 19, 2024
概括
一种天然化合物 (R) -aloesaponol-III-8-methyl ether,通过抑制TNF-α和激活蛋白酶体,显示出治疗神经退行性疾病的前景,提供了一种新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- 神经退行性疾病在全球范围内增加,没有有效的治疗方法.
- 患者的变化给精准医学方法带来了挑战.
- 作为ELAV家族成员的HuD蛋白对神经元可塑性和分化至关重要.
研究的目的:
- 识别具有针对神经退行性疾病的创新作用机制的新分子.
- 为了研究 (R) - 石 - III-8 - 甲基乙烯 (ASME) 作为治疗剂的潜力.
- 探索ASME作为TNF-α抑制剂和蛋白酶激活剂的双重作用.
主要方法:
- 使用SAFAN技术进行计算调查,以识别HuD结合分子.
- 从*Eremurus persicus*中提取和分离代谢物,包括 (R) -ASME和germichrysone.
- 在体外和细胞测试中评估ASME与HuD的结合亲和力及其蛋白质酶激活特性.
主要成果:
- 计算选确定了 (R) -ASME作为对HuD目标的强有力的绑定器.
- (R) -ASME被证实可以抑制TNF-α,这是一个关键的炎症性细胞因子.
- 在酶和细胞测试中,ASME表现出显著的蛋白酶激活.
结论:
- 由于其新的双重作用机制,ASME是神经退行性疾病的有前途的治疗候选药物.
- 准HuD和激活蛋白质酶是对抗神经退行性疾病的创新策略.
- 对ASME的进一步研究可能会导致对这些衰弱性疾病的有效治疗方法的开发.
相关概念视频
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:30Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39